Dioseve
Latest round
- Series A
Last raised
- Jun 2026
Total raised
- $15M
Investors
- 10
About Dioseve
a Dioseve, a biotechnology startup focuses on creating fertility treatment technologies that utilize induced pluripotent stem (iPS) cells, including products designed to facilitate the maturation of eggs outside the human body for vitro fertilization (IVF) and reduce patient burden. The CEO, Kazuma Kishida, has a background in biotechnology. Dioseve, Inc. specializes in advanced differentiation induction technology that enables the efficient conversion of induced pluripotent stem (iPS) cells into oocytes and ovarian somatic cells. This proprietary technology addresses previously unsolved challenges in reproductive biology and regenerative medicine, providing innovative solutions for applications such as fertility treatments and ovarian function restoration. The company targets a diverse range of stakeholders, including research institutions, healthcare providers, and biotechnology firms, seeking to enhance reproductive health and therapeutic options.Dioseve generates revenue through partnerships and collaborations with research institutions, healthcare organizations, and biotechnology firms, leveraging its unique technology to create high-value solutions. The company's business model includes direct B2B transactions, wherein clients engage in agreements to utilize Dioseve’s differentiation induction technology for research and clinical applications. Revenue streams are diversified through subscription agreements for ongoing access to their proprietary technologies and services, enabling continuous revenue generation from established partnerships. Specific pricing plans for their flagship products and services reflect the advanced nature of the technology, catering to the specialized needs of their clientele without publicly available pricing details.
Who invested in Dioseve
10 investors across 3 rounds
See all investors in Dioseve
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Dioseve
Who invested in Dioseve?
Dioseve has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Dioseve raised?
Dioseve has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Dioseve last raise money?
Dioseve's most recent round on record is a Series A, in Jun 2026.
What does Dioseve do?
a Dioseve, a biotechnology startup focuses on creating fertility treatment technologies that utilize induced pluripotent stem (iPS) cells, including products designed to facilitate the maturation of eggs outside the human body for vitro fertilization (IVF) and reduce patient burden.
Where is Dioseve headquartered?
Dioseve is headquartered in Tokyo, Japan.
Which VCs invest in companies like Dioseve?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Dioseve's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Dioseve? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.